AMA applauds FDA for approving naloxone product to prevent overdoses

| 2 Min Read

“The American Medical Association (AMA) applauds the Food and Drug Administration (FDA) for approving the nasal spray version of naloxone, a life-saving medication that can reverse the effects of an opioid overdose by restoring breathing and preventing death. The FDA’s swift action will widely increase accessibility to this medication that will help prevent more opioid-related overdoses and save more lives.

“The AMA has long advocated in support of a multi-pronged approach to addressing prescription drug abuse and diversion, which includes increasing access to naloxone for patients who need it.

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Physician looking out a window

Physicians in these 10 specialties are less likely to quit

| 6 Min Read
Perturbed patient holds up hands during an appointment

Only 1 in 3 doctors trusts insurers’ prior authorization promises

| 6 Min Read
Senior man looks off into the distance

As population ages, need for practicing geriatricians grows more acute

| 5 Min Read
Jason Mitchell, MD, featured on "Health vs. Hype" AMA podcast (episode 3)

9 things patients should know about taking creatine

| 5 Min Read